ER RIPTACs™ Drive Tumor Selective Cell Death in post-CDK4/6i Resistance Settings and Demonstrate Oral Efficacy in CDX and PDX Models

David E. Puleo, Matthew A. Perry, Michael B. Martin, Chris D. Forbes, Kelli M. Jones, Andrew McGovern, Abigail Hundt, Samantha Fasciano, Rebecca Stronk, Madeline P. King, Aiyana Ward, Keely Cooney-Walsh, Katia Howard, Cassidy Marshall, Eyal Attar, Kyle J. Eastman, Kanak Raina, Katherine J. Kayser-Bricker

Halda Therapeutics OpCo Inc, New Haven CT

PS1-10-08

Background

Methods

HLD-0117 Induces a Cooperative Ternary Complex and neo-PPI

RIPTAC Activity is Dependent on ER Expression *in vitro & in vivo*

HLD-0117 Induces Dose-Dependent TGI/Regressions in Endocrine-Sensitive Disease

HLD-0117 is Active in ER Dependent Disease

HLD-0117 Induces Cell Death in ER Co-Driven / Independent Disease

HLD-0117 Lacks Endometrial and Uterine Agonism

Conclusions

References

RESEARCH POSTER PRESENTATION DESIGN © 2015
www.PosterPresentations.com

Presented at San Antonio Breast Cancer Symposium, San Antonio, Texas. December 9-12, 2025.